Johnston SRD - Search Results

1

MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR⁺, HER2^--Advanced Breast Cancer.

Neven P, Johnston SRD, Toi M, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Conte P, Lu Y, Haddad N, Hurt KC, Llombart-Cussac A, Sledge GW. Neven P, et al. Among authors: johnston srd. Clin Cancer Res. 2021 Nov 1;27(21):5801-5809. doi: 10.1158/1078-0432.CCR-20-4685. Epub 2021 Aug 10. Clin Cancer Res. 2021. PMID: 34376533

2

Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer.

Johnston SR, Saccani-Jotti G, Smith IE, Salter J, Newby J, Coppen M, Ebbs SR, Dowsett M. Johnston SR, et al. Cancer Res. 1995 Aug 1;55(15):3331-8. Cancer Res. 1995. PMID: 7614468

3

Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer.

Johnston SR, Smith IE, Doody D, Jacobs S, Robertshaw H, Dowsett M. Johnston SR, et al. Cancer Res. 1994 Nov 15;54(22):5875-81. Cancer Res. 1994. PMID: 7954417 Clinical Trial.

4

Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer.

Ellis PA, Saccani-Jotti G, Clarke R, Johnston SR, Anderson E, Howell A, A'Hern R, Salter J, Detre S, Nicholson R, Robertson J, Smith IE, Dowsett M. Ellis PA, et al. Int J Cancer. 1997 Aug 7;72(4):608-13. doi: 10.1002/(sici)1097-0215(19970807)72:4<608::aid-ijc10>3.0.co;2-7. Int J Cancer. 1997. PMID: 9259399 Free article. Clinical Trial.

5

Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors.

Johnston SR, Lu B, Dowsett M, Liang X, Kaufmann M, Scott GK, Osborne CK, Benz CC. Johnston SR, et al. Cancer Res. 1997 Sep 1;57(17):3723-7. Cancer Res. 1997. PMID: 9288779

6

Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.

Newby JC, Johnston SR, Smith IE, Dowsett M. Newby JC, et al. Clin Cancer Res. 1997 Sep;3(9):1643-51. Clin Cancer Res. 1997. PMID: 9815855

7

In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.

Dowsett M, Jones A, Johnston SR, Jacobs S, Trunet P, Smith IE. Dowsett M, et al. Clin Cancer Res. 1995 Dec;1(12):1511-5. Clin Cancer Res. 1995. PMID: 9815951 Clinical Trial.

8

Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance.

Johnston SR, Lu B, Scott GK, Kushner PJ, Smith IE, Dowsett M, Benz CC. Johnston SR, et al. Clin Cancer Res. 1999 Feb;5(2):251-6. Clin Cancer Res. 1999. PMID: 10037172

9

Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.

Dowsett M, Pfister C, Johnston SR, Miles DW, Houston SJ, Verbeek JA, Gundacker H, Sioufi A, Smith IE. Dowsett M, et al. Clin Cancer Res. 1999 Sep;5(9):2338-43. Clin Cancer Res. 1999. PMID: 10499602 Clinical Trial.

10

Low-dose oral fluorouracil with eniluracil as first-line chemotherapy against advanced breast cancer: a phase II study.

Smith IE, Johnston SR, O'Brien ME, Hickish TF, de Boer RH, Norton A, Cirkel DT, Barton CM. Smith IE, et al. J Clin Oncol. 2000 Jun;18(12):2378-84. doi: 10.1200/JCO.2000.18.12.2378. J Clin Oncol. 2000. PMID: 10856097 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

256 results

Search Page